No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
Zhitong FinanceApr 25 19:30
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics with a Buy and maintains $40 price target.
Analyst UpgradesApr 25 19:25
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 663.36% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/01/2024 663.36% HC Wainwright & Co. →
BenzingaApr 25 19:24
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
TipRanksApr 25 18:25
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics (CAPR) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duch
MT NewswiresApr 25 03:21
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Yahoo FinanceApr 25 00:42
No Data
No Data